[1] PIHLSTROM B L, MICHALOWICZ B S, JOHNSON N W. Periodontal diseases[J]. Lancet, 2005,366(9499):1809-1820.
[2] GENCO R J, VAN DYKE T E. Prevention:Reducing the risk of CVD in patients with periodontitis[J]. Nat Rev Cardiol, 2010, 7(9):479-480.
[3] KEBSCHULL M, DEMMER R T, PAPAPANOU P N. "Gum bug, leave my heart alone!"-epidemiologic and mechanistic evidence linking periodontal infections and atherosclerosis[J]. J Dent Res, 2010, 89(9):879-902.
[4] LUNDBERG K, WEGNER N, YUCEL-LINDBERG T, et al. Periodontitis in RA-the citrullinated enolase connection[J]. Nat Rev Rheumatol, 2010, 6(12):727-730.
[5] HAN Y W, WANG X. Mobile microbiome:oral bacteria in extra-oral infections and inflammation[J]. J Dent Res, 2013, 92(6):485-491.
[6] MADIANOS P N, BOBETSIS Y A, OFFENBACHER S. Adverse pregnancy outcomes (APOs) and periodontal disease:pathogenic mechanisms[J]. J Clin Periodontol, 2013, 40(Suppl 14):S170-S180.
[7] WHITMORE S E, LAMONT R J. Oral bacteria and cancer[J]. PLoS Pathog, 2014, 10(3):e1003933.
[8] DOMINY S S, LYNCH C, ERMINI F, et al. Porphyromonas gingivalis in Alzheimer's disease brains:Evidence for disease causation and treatment with small-molecule inhibitors[J]. Sci Adv, 2019, 5(1):eaau3333.
[9] GEISINGER M L, MEALEY B L, SCHOOLFIELD J, et al. The effectiveness of subgingival scaling and root planing:an evaluation of therapy with and without the use of the periodontal endoscope[J]. J Periodontol, 2007, 78(1):22-28.
[10] GIBSON F C, GENCO C A. Porphyromonas gingivalis mediated periodontal disease and atherosclerosis:disparate diseases with commonalities in pathogenesis through TLRs[J]. Curr Pharm Des, 2007, 13(36):3665-3675.
[11] ARMITAGE G C. Classifying periodontal diseases:a long-standing dilemma[J]. Periodontol 2000, 2002, 30:9-23.
[12] HAJISHENGALLIS G. Toll gates to periodontal host modulation and vaccine therapy[J]. Periodontol 2000, 2009, 51:181-207.
[13] GAFFEN S L, HAJISHENGALLIS G. A new inflammatory cytokine on the block:re-thinking periodontal disease and the Th1/Th2 paradigm in the context of Th17 cells and IL-17[J]. J Dent Res, 2008, 87(9):817-828.
[14] GRAVES D. Cytokines that promote periodontal tissue destruction[J]. J Periodontol, 2008, 79(8 Suppl):1585-1591.
[15] HAJISHENGALLIS G. The inflammophilic character of the periodontitis-associated microbiota[J]. Mol Oral Microbiol, 2014, 29(6):248-257.
[16] ROSIER B T, MARSH P D, MIRA A. Resilience of the oral microbiota in health:mechanisms that prevent dysbiosis[J]. J Dent Res, 2018, 97(4):371-380.
[17] HAJISHENGALLIS G, KAJIKAWA T, HAJISHENGALLIS E, et al. Complement-dependent mechanisms and interventions in periodontal disease[J]. Front Immunol, 2019, 10:406.
[18] CSERHALMI M, PAPP A, BRANDUS B, et al. Regulation of regulators:role of the complement factor H-related proteins[J]. Semin Immunol, 2019,45:101341.
[19] DZIK S. Complement and coagulation:cross talk through time[J]. Transfus Med Rev, 2019,33(4):199-206.
[20] HAJISHENGALLIS G. Complement and periodontitis[J]. Biochem Pharmacol, 2010, 80(12):1992-2001.
[21] ROUMENINA L T, BARTOLUCCI P, PIRENNE F. The role of complement in post-transfusion hemolysis and hyperhemolysis reaction[J]. Transfus Med Rev, 2019,33(4):225-230.
[22] DAMGAARD C, HOLMSTRUP P, VAN DYKE T E, et al. The complement system and its role in the pathogenesis of periodontitis:current concepts[J]. J Periodont Res, 2015, 50(3):283-293.
[23] HAJISHENGALLIS G, MAEKAWA T, ABE T, et al. Complement involvement in periodontitis:molecular mechanisms and rational therapeutic approaches[J]. Adv Exp Med Biol, 2015, 865:57-74.
[24] KAPFERER-SEEBACHER I, PEPIN M, WERNER R, et al. Periodontal ehlers-danlos syndrome is caused by mutations in C1R and C1S, which encode subcomponents C1r and C1s of complement[J]. Am J Hum Genet, 2016, 99(5):1005-1014.
[25] KAJIKAWA T, BRIONES R A, RESUELLO R R G, et al. Safety and efficacy of the complement inhibitor AMY-101 in a natural model of periodontitis in non-human primates[J]. Mol Ther Methods Clin Dev, 2017, 6:207-215.
[26] VIVES-SOLER A, CHIMENOS-KÜSTNER E. Effect of probiotics as a complement to non-surgical periodontal therapy in chronic periodontitis:a systematic review[J]. Med Oral Patol Oral Cir Bucal, 2020, 25(2):e161-e167.
[27] MIYAKE K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors[J]. Semin Immunol, 2007, 19(1):3-10.
[28] SCHAEFER L. Extracellular matrix molecules:endogenous danger signals as new drug targets in kidney diseases[J]. Curr Opin Pharmacol, 2010, 10(2):185-190.
[29] SATO T, ABE E, JIN C H, et al. The biological roles of the third component of complement in osteoclast formation[J]. Endocrinology, 1993, 133(1):397-404.
[30] TU Z D, BU H, DENNIS J E, et al. Efficient osteoclast differentiation requires local complement activation[J]. Blood, 2010, 116(22):4456-4463.
[31] GUO R F, WARD P A. Role of C5a in inflammatory responses[J]. Annu Rev Immunol, 2005, 23:821-852.
[32] OKROJ M, HEINEGÅRD D, HOLMDAHL R, et al. Rheumatoid arthritis and the complement system[J]. Ann Med, 2007, 39(7):517-530.
[33] RITTIRSCH D, FLIERL M A, NADEAU B A, et al. Functional roles for C5a receptors in sepsis[J]. Nat Med, 2008, 14(5):551-557.
[34] MYDEL P, TAKAHASHI Y, YUMOTO H, et al. Roles of the host oxidative immune response and bacterial antioxidant rubrerythrin during Porphyromonas gingivalis infection[J]. PLoS Pathog, 2006, 2(7):e76.
[35] HAJISHENGALLIS G. Immunomicrobial pathogenesis of periodontitis:keystones, pathobionts, and host response[J]. Trends Immunol, 2014, 35(1):3-11.
[36] WINGROVE J A, DISCIPIO R G, CHEN Z, et al. Activation of complement components C3 and C5 by a cysteine proteinase (gingipain-1) from Porphyromonas (Bacteroides) gingivalis[J]. J Biol Chem, 1992, 267(26):18902-18907.
[37] HAJISHENGALLIS G, WANG M, LIANG S, et al. Subversion of innate immunity by periodontopathic bacteria via exploitation of complement receptor-3[J]. Adv Exp Med Biol, 2008, 632:203-219.
[38] WANG M, KRAUSS J L, DOMON H, et al. Microbial hijacking of complement-toll-like receptor crosstalk[J]. Sci Signal, 2010, 3(109):ra11.
[39] SCHOENGRAF P, LAMBRIS J D, RECKNAGEL S, et al. Does complement play a role in bone development and regeneration?[J]. Immunobiology, 2013, 218(1):1-9.
[40] SEPPÄNEN M, LOKKI M L, NOTKOLA I L, et al. Complement and c4 null alleles in severe chronic adult periodontitis[J]. Scand J Immunol, 2007, 65(2):176-181.
[41] ROUMENINA L T, RAYES J, FRIMAT M,et al. Endothelial cells:source, barrier, and target of defensive mediators[J]. Immunol Rev, 2016, 274(1):307-329.
[42] WANG H B, RICKLIN D, LAMBRIS J D. Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4[J]. Proc Natl Acad Sci U S A, 2017, 114(41):10948-10953.
[43] HAJISHENGALLIS G, LIANG S, PAYNE M A, et al. Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement[J]. Cell Host Microbe, 2011, 10(5):497-506.
[44] RICKLIN D, HAJISHENGALLIS G, YANG K, et al. Complement:a key system for immune surveillance and homeostasis[J]. Nat Immunol, 2010, 11(9):785-797.
[45] EHLERS M R. CR3:a general purpose adhesion-recognition receptor essential for innate immunity[J]. Microbes Infect, 2000, 2(3):289-294.
[46] HAJISHENGALLIS G, SHAKHATREH M A, WANG M, et al. Complement receptor 3 blockade promotes IL-12-mediated clearance of Porphyromonas gingivalis and negates its virulence in vivo[J]. J Immunol, 2007, 179(4):2359-2367.
[47] LIANG S, KRAUSS J L, DOMON H, et al. The C5a receptor impairs IL-12-dependent clearance of Porphyromonas gingivalis and is required for induction of periodontal bone loss[J]. J Immunol, 2011, 186(2):869-877.
[48] MAEKAWA T, ABE T, HAJISHENGALLIS E, et al. Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis[J]. J Immunol, 2014, 192(12):6020-6027. |
